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Abstract
Background: Chemotherapy for breast cancer often deteriorates quality of life, augments fatigue, and induces neutropenia. Mistletoe 
preparations are frequently used by cancer patients in Central Europe. Physicians have reported better quality of life in breast cancer 
patients additionally treated with mistletoe preparations during chemotherapy. Mistletoe preparations also have immunostimulant prop-
erties and might therefore have protective effects against chemotherapy-induced neutropenia.
Patients and Methods: We conducted a prospective randomized open label pilot study with 95 patients randomized into three groups. 
Two groups received Iscador® M special (IMS) or a different mistletoe preparation, respectively, additionally to chemotherapy with six 
cycles of cyclophosphamide, adriamycin, and 5-fluoro-uracil (CAF). A control group received CAF with no additional therapy. Here we 
report the comparison IMS (n = 30) vs. control (n = 31). Quality of life including fatigue was assessed with the European Organization 
for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30). Neutropenia was defined as neutrophil 
counts 1,000/µl and assessed at baseline and one day before each CAF cycle.
Results: In the descriptive analysis all 15 scores of the EORTC-QLQ-C30 showed better quality of life in the IMS group compared to 
the control group. In 12 scores the differences were significant (p  0.02) and nine scores showed a clinically relevant and significant 
difference of at least 5 points. Neutropenia occurred in 3/30 IMS patients and in 8/31 control patients (p = 0.182).
Conclusions: This pilot study showed an improvement of quality of life by treating breast cancer patients with IMS additionally to CAF. 
CAF-induced neutropenia showed a trend to lower frequency in the IMS group.
Keywords: mistletoe thereapy, breast cancer, randomized clinical trial, quality of life, neutropeniaTröger et al
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Introduction
Background
Quality of life is frequently deteriorated during and 
after  chemotherapy  for  cancer.1  Besides  nausea, 
emesis  and  pain,  fatigue  is  a  frequent  complaint, 
reported  by  70%–100%  of  the  patients.2  Recent 
research  has  shown  that  fatigue  lasts  for  months 
after the last cycle of chemotherapy.2 Three types 
of  fatigue  are  distinguished:  general,  physical, 
and  mental;  the  latter  being  related  to  reduced 
activity, depression, anxiety, and mood disorders.3,4 
Fatigue,  insomnia  and  daytime  sleepiness  are 
augmented  during  and  after  chemotherapy  with 
cyclophosphamide  and  5-FU  combined  with 
methotrexate  (CMF)  or  anthracyclines  (CAF).5 
One can conclude that fatigue is one of the major 
concerns for patients with cancer.6,7
Mistletoe therapy
Physicians have reported better quality of life in breast 
cancer  patients  additionally  treated  with  mistletoe 
preparations  during  chemotherapy,  compared  to 
patients receiving chemotherapy alone.8–12 Mistletoe 
preparations  also  have  immunostimulant  and 
DNA-protecting  properties13,14  and  might  therefore 
have protective effects against chemotherapy-induced 
neutropenia.15
In  Central  Europe,  mistletoe  preparations  are 
widely used for adjuvant cancer therapy, especially 
by  breast  cancer  patients.  In  Germany,  70%  of 
cancer patients use unconventional treatments, and 
randomized  trials  of  mistletoe  preparations  are 
difficult to conduct because of non-compliance and 
low recruitment rates due to therapy preferences.16–19 
Mistletoe preparations10,16 as adjunct to CMF12,16 or 
other  chemotherapies  for  breast  cancer  and  other 
types of cancer10 have been examined in a few clinical 
studies showing a benefit in EORTC-QLQ-C3016 and 
other quality of life scores.10,12
This  randomised  clinical  trial  assessed 
mistletoe  effects  during  CAF  chemotherapy  for 
breast  cancer.  The  aim  was  to  explore  whether 
the  EORTC-QLQ-C30  is  a  suitable  instrument  to 
detect differences between patients with early breast 
cancer  receiving  CAF  with  and  without  additional 
mistletoe therapy and whether such study is feasible 
in Serbia, a country where mistletoe preparations are 
not available.
Methods
Objectives
The objectives of this pilot study were to determine 
the clinical response (quality of life including fatigue) 
and  neutropenia  in  breast  cancer  patients  during 
CAF. Our hypotheses were: Breast cancer patients 
receiving mistletoe preparations during six cycles of 
consecutive treatment with CAF will show a better 
quality of life including fatigue, and less neutropenia 
compared to patients receiving CAF alone.
Design
We conducted a prospective randomized open label 
study with equal-size randomization into three groups. 
All three groups received six cycles of  CAF. In addition, 
one group received Iscador® M special (IMS), another 
group received a different mistletoe preparation and 
a control group had no additional therapy. Here we 
report the comparison IMS vs. control.
Participants
Breast cancer patients in the stages T1–3N0–2M0 treated 
at the Institute of Oncology and Radiology, National 
Cancer Research Centre of Serbia in Belgrade (IORS) 
and prescribed six consecutive cycles of CAF after 
surgery were assessed for eligibility.
Additional inclusion criteria were female gender, 
age  18  years,  Karnofsky-Index  60,  leucocytes 
3‚000/mm³, thrombocytes 100‚000/mm³, serum 
creatinine  2  mg%,  serum  glutamic  oxaloacetic 
transaminase (SGOT), and serum glutamic pyruvic 
transaminase (SGPT) 2.5 × the upper institutional 
limits.
Exclusion  criteria  were  pregnancy  or  lactation, 
metastases,  planned  radiation  or  hormone  therapy 
during  six  consecutive  cycles  of  CAF,  use  of 
immunostimulant  or  immunosuppressive  agents 
(e.g. corticosteroids) except for nausea and emesis; 
current use of other investigational agents, clinically 
relevant physical or mental illness such as serious 
infections, hepatic, renal or other organ dysfunction 
or major depression; alcohol abuse, alcoholism, oral 
or parenteral drug abuse, and methadone treatment.
Randomization
The chance to be allocated to any of the three groups 
(IMS, other mistletoe preparation, control) was 1:1:1. Mistletoe therapy during chemotherapy of early breast cancer
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For randomization variable block sizes were used. 
No stratification took place prior to randomization. 
The  randomization  sequence  was  generated  by 
Clinical Research Dr. Tröger (CRDT), using SPSS® 
(SPSS®  14.0.1,  SPSS  Inc.,  Chicago,  Ill,  USA). 
Allocation concealment was implemented by using 
sealed envelopes, prepared by CRDT. Patients were 
enrolled  by  investigators  at  the  Outpatient  Clinic, 
IORS, while the sealed randomization envelopes were 
stored in the Department of Study Coordination, IORS 
and released consecutively for each enrolled patient.
interventions
CAF was administered in six cycles with a three-week 
interval between each cycle. The scheduled dosage 
was 500 mg Cyclophosphamide, 50 mg Adriamycin, 
and 500 mg 5-FU per 1 m² skin surface applied at 
one  day.  All  patients  received  antiemetic  therapy 
with  a  single  dose  of  Ondansetrone  chloride 
8 mg, Dexamethasone 8 mg, and Ranitidine 50 mg, 
respectively, administered prior to each CAF cycle.
One dropout patient in the control group received 
only three CAF cycles, while all other patients received 
the  six  scheduled  CAF  cycles.  The  applied  dose 
intensities (DI) of Cyclophosphamide, Adriamycin, 
and 5-FU (DI in mean mg/m² per week; ± standard 
deviation) were 160.8 ± 5.5 mg, 16.1 ± 0.5 mg, and 
160.8 ± 5.5 mg, respectively, in the IMS group and 
157.1 ± 15.6 mg, 15.7 ± 1.6 mg, and 157.1 ± 15.6 mg, 
respectively,  in  the  control  group.  The  results 
correspond to 99% of planned DI in the IMS group 
and 96% of planned DI in the control group. No other 
antineoplastic or immunomodulating therapies were 
applied during the study.
Patients randomly allocated to additional therapy 
with IMS received Iscador®  M special (IMS; fermented 
aqueous extract of Viscum album from apple tree, 
fresh plant material, ratio of plant to extract = 1:5). 
IMS was manufactured by Weleda AG, Schwäbisch 
Gmünd,  Germany  and  prepared  in  1  ml  ampoules 
for injection, each ampoule containing the fermented 
extract of 0.01, 0.1, 1, 2, or 5 mg of fresh mistletoe 
herb, respectively, in isotonic saline solution. IMS was 
administered by subcutaneous injections of 1 ml IMS 
into  the  upper  abdominal  region  three  times  per 
week (i.e. Monday, Wednesday, Friday). The patients 
were  instructed  to  inject  IMS  themselves.  The 
dosage of IMS was increased stepwise: 2 × 0.01 mg, 
2 × 0.1 mg, 11 × 1 mg, 8 × 2 mg, remaining doses 
5  mg.  Dose-dependent  inflammatory  reactions  at 
the  injection  site  (redness,  swelling,  sometimes 
accompanied  by  itching)  were  monitored.  If  such 
reactions exceeded 5 cm in diameter, the dosage was 
decreased or the therapy was paused until the reactions 
had ceased. An average of 54.1 ± 2.3 injections with 
altogether 174.80 ± 26.34 mg of IMS per patient were 
administered in the IMS group.
Outcomes
Outcomes were quality of life and neutropenia. Quality 
of life was assessed using the European Organization 
for Research and Treatment of Cancer Quality of Life 
Questionnaire  (EORTC-QLQ-C30)  in  the  official 
Serbian  translation.20  The  EORTC-QLQ-C30  has 
30 questions and is analysed in 15 scores: six scores for 
functioning and nine symptom scores (Table 2). The 
EORTC-QLQ-C30 was documented by the patients at 
seven visits: before each CAF cycle and three weeks 
after the 6th CAF cycle. Neutropenia was defined as 
neutrophil count 1,000/µl in the peripheral blood 
and  assessed  one  day  before  each  CAF  cycle  and 
three weeks after the 6th CAF cycle.
Assessment of adverse events (Ae)
Adverse  events  were  assessed  by  interviewing  the 
patients  and  by  analysing  the  laboratory  results  at 
each visit. Local reactions to IMS less than 5 cm in 
diameter were not considered as adverse events.
sample size
A  sample  size  of  90  patients  (30  per  group)  was 
considered to be sufficient for this pilot study.
Blinding
The study was not placebo controlled because the 
typical  and  time-dependent  reactions  following 
s.c.  injections  of  mistletoe  extracts  (reactions  at 
the  injection  site,  increased  body  temperature, 
flu-like  symptoms)  cannot  be  imitated  by  a 
pseudo-placebo.
statistical methods
Statistical analysis (SPSS® 14.0) was performed on the 
intention-to-treat-population. An alternative analysis 
of the per-protocol sample, excluding one dropout 
patient in the control group, yielded very similar results Tröger et al
38  Breast Cancer: Basic and Clinical Research  2009:3
(data not shown). All results of the statistical analysis 
have exclusively hypothesis-generating character.
For each quality of life score (EORTC QLQ-C30), 
the mean change from baseline during follow-up in 
each group was compared between the IMS group, 
the group with the other mistletoe preparation and the 
control group, using nonparametric marginal models 
according  to  Brunner21  with  therapy  as  whole-plot 
factor  and  time  as  sub-plot  factor  and  a  possible 
interaction  between  these  two  factors  (results  not 
shown). As  a  sensitivity  assessment,  a  parametric 
covariance pattern model was also applied and found 
to qualitatively concur with the nonparametric results. 
For  a  better  representability,  the  estimates  of  this 
parametric model will be shown. Post-hoc analyses 
of differences between the IMS group and control 
group were performed using the Dunnett T3-Test.
Neutropenia was assessed by measuring the number 
of  patients  with  neutrophils  1,000/µl  during  the 
study. For neutropenia, the group difference between 
IMS group and control group was analysed by Fisher’s 
exact test according to the sequential rejective Holm 
procedure.
Adherence to regulations
The study was approved by the Ethics Committee 
of  the  National  Cancer  Research  Center  of  Serbia 
without modifications (date: 3 October 2005) and by 
the Serbian Drug Agency (date: 01 November 2005). 
Due to its pilot character, this study was not registered 
in a public study registry. The study was conducted 
in  compliance  with  the  Declaration  of  Helsinki, 
Good Clinical Practice guidelines, and national laws. 
A patient insurance was provided for all participants. 
All patients provided signed informed consent prior 
to  inclusion.  CRDT  was  responsible  for  planning, 
conduct,  monitoring,  and  analysis  of  the  study. 
Two audits at CRDT and one at the study site were 
performed  by  the  two  sponsors  during  the  study. 
No violation of Good Clinical Practice was detected.
Results
Recruitment, participant flow, 
assessment, and numbers analysed
From 14 December 2005 to 15 February 2007 a total 
of 123 breast cancer patients were prescribed CAF 
and assessed for eligibility at the study centre IORS. 
28 patients were not included and 95 patients were 
included  and  randomized  into  3  groups:  CAF  and 
IMS (n = 30), CAF and another mistletoe preparation 
(n = 34), and CAF without additional therapy (n = 31). 
One patient in the control group was withdrawn from 
further CAF therapy after three cycles of CAF because 
of heart disease (Fig. 1).
The EORTC-QLQ-C30 was evaluable for 99.5% 
(209  of  210)  of  visits  in  the  IMS  group,  and  for 
97.2% (211 of 217) of visits in the control group. The 
neutrophil count was assessed at 99.5% (209 of 210) 
of visits in the IMS group and 98.2% (213 of 217) of 
visits in the control group.
Baseline data of the patient groups
The IMS group and the control group did not differ 
significantly regarding age, tumour stage, body mass 
index, physical status, vital signs, previous diseases, 
EORTC-QLQ-C30 scores (Table 1). No neutropenia 
was detected at baseline.
Quality of life during chemotherapy
During chemotherapy with CAF a deterioration of 
quality of life occurred in all 15 EORTC-QLQ-C30 
scores in the control group and in six scores in the 
IMS  group. A  clinical  relevant  deterioration  of  at 
least 5 points was found in eight scores of the control 
group and in two scores in the IMS group (Table 3). 
The most pronounced deteriorations were observed 
for  nausea/emesis  (17.2  score  points)  and  fatigue 
(8.2) after the 2nd cycle of CAF and insomnia (13.1) 
and diarrhoea (11.9) after the 3rd cycle.
In the adjusted analyses, mean differences from 
baseline were compared between the two groups for 
each EORTC-QLQ-C30 score: All 15 comparisons 
favoured the IMS group, 12 comparisons showed 
significant differences with p-values ranging from 
0.017 to 0.001. Clinically relevant differences of at 
least 5 points favouring the IMS group were observed 
for nine EORTC-QLQ-C30 scores (Table 2).
In  descriptive  analyses,  the  differences  from 
baseline for each score at each of the six follow-up 
assessments were compared between the two groups: 
86 out of 90 differences favoured the IMS group, while 
four differences favoured the control group (Fig. 2). 
Furthermore, the maximum between-group difference 
for each EORTC-QLQ-C30 score during follow-up 
was analysed: All 15 differences favoured the IMS 
group:  maximum  differences  of  at  least  15  points Mistletoe therapy during chemotherapy of early breast cancer
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were  found  in  four  scores  (Role  Function,  Social 
Function, Pain, and Insomnia), 10–15 point differences 
were found in five scores (Global Health, Emotional 
function, Constipation, Diarrhoea, Appetite loss), and 
differences 10 points were found in the remaining 
six scores.
neutropenia during chemotherapy
Neutropenia  (1,000/µl)  was  detected  three  times 
in three different patients of the IMS group and nine 
times in eight different patients of the control group. 
The patients with neutropenia are comparable across 
the groups (Table 3). Odds ratio for the proportion of 
patients with neutropenia in IMS group vs. control 
group was 0.32 (95% confidence interval 0.08–1.35). 
Using Fisher’s exact test according to the sequential 
rejective Holm procedure, a trend (p = 0.182) towards 
less neutropenia in the IMS group was found.
Adverse events related to iMs injections
Localized  skin  reactions  to  IMS  exceeding  5  cm 
diameter occurred in six patients. The frequency of 
these reactions was 0.49% (eight reactions in 1,618 
injections). No other adverse events related to IMS 
occurred.
Discussion
This  randomized  pilot  study  assessed  quality  of 
life  (EORTC-QLQ-C30)  and  neutropenia  in  early 
breast cancer patients undergoing CAF chemotherapy. 
Iscador M special 
n = 30 
control
n = 31
Other mistletoe 
therapy n = 34
completed study 
n = 30 
completed study
n = 30 
Drop-out
n = 1
Drop-out
n = 0
Patient has been 
withdrawn from 
CAF because of 
an heart disease.  
Randomized
n = 95
not  randomized
Reasons for not being randomized: 
– no informed consent: n =11 
– Failed the eligibility criteria: n = 9 
– no study medication available at the 
beginning of the study: n = 5 
– Travel distance: n = 3 
Assessed for eligibility
n = 123 
Figure 1. Detailed flow chart of the patient disposition.Tröger et al
40  Breast Cancer: Basic and Clinical Research  2009:3
Table 1. Baseline status.
Group
IMs (n = 30) control (n = 31) p values
Age in years (mean, ±sD; t-test) 48.4 ± 7.5 50.8 ± 8.0 0.228
Tumour status (n; Chi square test)
  Tumour classification 0.879
    T1 7 9
    T2 21 19
    T3 1 2
    Tx 1 1
  Pos. lymph nodes 0.343
    n0 10 16
    n1 19 14
    n2 1 1
  Tumour grade 0.963
    g1 1 1
    g2 24 24
    g3 5 6
Menopause status (n; Kruskal-Wallis test) 0.349
  Premenopausal 17 13
  Perimenopausal 2 1
  Postmenopausal 11 17
Receptor status estrogen 0.714
  + 20 17
  - 8 12
  Unknown 2 2
Receptor status progesteron 1.000
  + 18 19
  - 10 10
Unknown 2 2
Body Mass index (mean, ±sD; t-test) 27.0 ± 6.3 25.6 ± 4.7 0.709
Karnofsky-index (mean, ±sD) 100 ± 0.0 100 ± 0.0
Abnormal findings on physical examination (n) 0 0
Vital signs (mean, ±sD; t-test)
  Blood pressure systolic mm(hg) 130.0 ± 20.0 132.2 ± 19.0 0.661
  Blood pressure diastolic mm(hg) 81.7 ± 12.5 83.6 ± 13.6 0.568
  Pulse (/m) 82.3 ± 13.4 77.1 ± 10.1 0.094
  Temperature (°C) 36.5 ± 0.1 36.6 ± 0.1 0.268
Previous diseases (n) 0 0
Primary endpoints
  neutropenia (n) 0 0
(Continued)Mistletoe therapy during chemotherapy of early breast cancer
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Table 1. (Continued)
Group
  IMs (n = 30) control (n = 31) p values
    eORTC-QLQ-C30 (mean, ±sD; Mann-Whitney U-test)
    global health status 67.8 ± 20.4 68.5 ± 18.3 0.868
    Physical functioning 86.0 ± 14.2 86.0 ± 12.4 0.852
    Role functioning 65.5 ± 20.9 73.0 ± 16.9 0.143
    emotional functioning 75.8 ± 20.1 74.1 ± 18.1 0.623
    Cognitive functioning 85.0 ± 20.7 79.3 ± 23.4 0.267
    social functioning 76.7 ± 19.4 80.5 ± 18.9 0.424
    Fatigue 22.6 ± 17.2 25.7 ± 19.5 0.593
    nausea and vomiting 3.4 ± 9.3 2.9 ± 7.8 0.959
    Pain 21.7 ± 21.5 16.1 ± 20.6 0.210
    Dyspnoea 4.6 ± 14.7 3.4 ± 10.3 0.965
    insomnia 16.8 ± 21.1 23.0 ± 31.0 0.557
    Appetite loss 12.6 ± 22.6 10.3 ± 20.1 0.625
    Constipation 7.8 ± 14.3 6.9 ± 13.7 0.808
    Diarrhoea 2.2 ± 8.5 2.3 ± 8.6 0.972
    Financial difficulties 23.3 ± 23.4 20.7 ± 30.1 0.358
Patients  receiving  IMS  in  addition  to  CAF  had 
significantly  better  quality  of  life  and  showed 
a  trend  towards  less  neutropenia,  compared  to 
patients receiving CAF alone. IMS therapy was well 
tolerated.
Strengths of this study include a high recruitment 
rate, detailed assessments of therapy implementation, 
high  therapy  compliance,  and  very  low  dropout 
rates. Since 83% of eligible patients were included 
and  randomized,  the  results  of  this  study  would 
seem  to  be  generalizable  to  breast  cancer  patients 
(T1–3N0–2M0)  receiving  CAF  without  any  other 
concomitant therapies.
Due  to  the  open-label  design,  the  study  cannot 
distinguish  between  direct  drug  effects  on  quality 
of  life  and  possible  indirect  effects  from  therapy 
expectations, therapy administration etc. in the IMS 
group. This is a general limitation to all mistletoe 
studies:  mistletoe  injections  frequently  cause 
local  reactions  at  the  injection  site,  elevated  body 
temperature and flu-like symptoms. These symptoms 
cease within hours or days after exposure and may 
recur on repeated injections. Therefore, patients and 
physicians can easily guess if mistletoe extracts are 
administered. This was confirmed in a double-blind 
study, where all patients in the mistletoe group as 
well as their physicians were unblinded.16 A pseudo-
placebo causing the same combination of time-limited 
symptoms—without  specific  effects  on  quality  of 
life—has not yet been constructed.
Generally, medication trials are blinded to separate 
pharmacological  effects  from  placebo  effects. 
However, the lack of blinding may not necessarily 
have  had  relevant  effects  on  the  results  of  this 
study: An updated Cochrane review of randomised 
trials comparing placebo to no treatment found no 
significant placebo effects on eight out of ten evaluable 
indications, small effects on self-reported pain and 
moderate effects on phobia. Even these effects might 
have been confounded by biases.22–24
This study was designed as a pilot study, and the 
limited  sample  size  of  30  patients  per  group  does 
not allow for hypothesis confirmation. Nevertheless 
significant differences in 12 of 15 EORTC-QLQ-C30 
scores favouring the IMS group were found. Nine of 
these scores showed a clinically relevant difference 
of at least 5 points. The latter scores include pain, 
nausea,  emesis  and  insomnia,  which  are  highly 
relevant symptoms in patients during chemotherapy 
with CAF.Tröger et al
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Table 2. eORTC QLQ-C30 scores: mean change from baseline.
eORTc QLQ-c30 score Mean change from baseline
Quality of life IMs (n = 30) control (n = 31) Difference 95% Confidence interval p-value
global health status 2.77 -0.15 2.92 -2.15 to 7.98 0.393
Physical functioning -0.52 -4.08 3.56 0.61 to 6.51 0.014*
Role functioning 12.88 -1.21 14.09 9.02 to 19.16 0.001*
emotional functioning 3.73 -2.62 6.35 2.15 to 10.54 0.001*
Cognitive functioning 1.81 -2.28 4.10 -0.33 to 8.53 0.076
social functioning 2.08 -5.66 7.74 3.37 to 12.12 0.001*
Fatigue 0.93 5.84 -4.92 -8.78 to -1.05 0.009*
nausea and vomiting 7.02 14.60 -7.58 -12.25 to -2.91 0.001*
Pain -9.81 2.66 -12.47 -16.85 to -8.08 0.001*
Dyspnoea -2.32 1.38 -3.70 -6.79 to -0.60 0.015*
insomnia -2.53 5.72 -8.25 -13.42 to -3.09 0.001*
Appetite loss -1.35 5.30 -6.64 -12.28 to -1.01 0.017*
Constipation 7.21 8.33 -1.12 -6.53 to 4.29 1.000
Diarrhoea 0.16 6.27 -6.11 -9.47 to -2.75 0.001*
Financial difficulties 2.10 11.04 -8.94 -14.21 to -3.67 0.001*
Difference of the mean of all six follow-up assessments from the baseline: better quality of life is indicated by higher values in the first six scores and by 
lower scores in the following nine symptom scores.
*Significant difference in the post hoc Dunnett test.
Table 3. List of patients experiencing a neutropenia during CAF.
Group ID Visit no. Date (Visit) Age stage T n M G Leucocytes/nl neutrophils/nl
iMs 37 7 20/10/2006 60 2 2 1 0 2 2.9 0.9
44 7 03/11/2006 44 2 3 1 0 2 1.8 0.4
60 2 18/09/2006 51 2 1 0 0 2 6.7 0.6
Control 13 3 26/04/2006 32 2 2 1 0 2 2.8 0.9
33 5 29/08/2006 60 2 2 0 0 2 2.4 0.9
51 7 08/12/2006 66 2 2 1 0 2 1.3 0.3
56 7 21/12/2006 53 2 2 1 0 2 3.5 0.9
62 7 31/01/2007 62 2 1 1 0 2 2.5 0.8
66 7 23/01/2007 44 1 1 0 0 2 2.4 0.8
87 6 26/03/2007 45 2 2 1 0 2 3.3 0.3
90 6 29/03/2007 52 2 1 0 0 3 2.6 0.8
90 7 19/04/2007 52 2 1 0 0 3 2.7 0.9
Three patients of the iMs group and eight patients of the control group. experienced a neutropenia (p = 0.182; 2-sided Fishers exact test).Mistletoe therapy during chemotherapy of early breast cancer
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Figure 2. Graphs of the 15 scores of the EORTC-QLQ-C30. The filled markers  represent the iMs group whereas the empty squares  represent the 
control group. The mean difference from baseline of the eORTC score (mean; ± sD) is displayed for each visit. in the 6 function scores a higher qualtiy of 
life is represented by higher values. in the 9 symptom scores a higher quality of life is represented by lower values.
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An  important  problem  which  may  occur  during 
chemotherapy with CAF is neutropenia. Neutropenia 
is the limiting factor for a continuing chemotherapy 
and may be harmful to the patients. This study is the 
first randomized trial providing data on the incidence 
of CAF-induced neutropenia during additive therapy 
with IMS. A trend towards less neutropenia in the IMS 
group was found. This should be further investigated 
in confirmatory studies with adequate sample size. It is 
recommended to include measurements of neutrophils 
on day 7, 9 and day 11 after chemotherapy in order to 
assess the nadir of the neutropenia during CAF therapy.
Future studies of mistletoe effects on quality of 
life  in  cancer  patients  undergoing  chemotherapy Tröger et al
44  Breast Cancer: Basic and Clinical Research  2009:3
should  also  include  specific  instruments  to  assess 
cancer-related  fatigue  and  pain.  In  our  study  the 
effects of IMS on quality of life increased over time 
with the largest effects observed at the last follow-up 
visit. A longer follow-up period of 6–12 months might 
show additional long term benefits of IMS therapy.
conclusions
In this randomized pilot study, additional treatment 
with mistletoe therapy (Iscador® M special) improved 
quality of life and showed a trend towards reduction 
of neutropenia in patients with early breast cancer 
receiving  CAF  chemotherapy.  These  promising 
results should be confirmed in a larger study.
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